Publications

The outcomes of children born to mothers with autoimmune rheumatic diseases

Lancet Rheumatol 2024:S2665-9913(24)00096-1 doi: 10.1016/S2665-9913(24)00096-1 Epub ahead of print

Andreoli L,

Andersen J,

Avcin T,

Chambers CD,

Fazzi EM,

Marlow N,

Wulffraat NM,

Tincani A

This Series paper by Andreoli, et al. provides a comprehensive overview of the literature for pregnancy outcomes for mothers with autoimmune rheumatic disease, and provides guidance on discussing these topics with patients. They also provide a list of frequently asked questions related to pregnancy and children by women with autoimmune rheumatic diseases.

Keywords:

• IL-6,
• Outcomes,
• Pregnancy / Fertility,
• Recommendations,
• TNF

Immunogenicity and Safety of Adjuvanted Recombinant Zoster Vaccine in Rheumatoid Arthritis Patients on Anti-Cellular Biologic Agents or JAK Inhibitors: A Prospective Observational Study

Int JMol Sci 2023;24(8):6967 doi 10.3390/ijms24086967

Venerito V,

Stefanizzi P,

Cantarini L,

Lavista M,

Galeone MG,

Lorenzo AD,

Iannone F,

Tafuri F,

Lopalco G

A prospective observational study showed that recombinant zoster vaccine (RZV) immunogenicity is not impaired in RA patients on JAK inhibitors or anti-cellular bDMARDs.

Keywords:

• Efficacy,
• Vaccination

Evaluación de la respuesta a la vacuna 13-valente neumocócica conjugada en pacientes con artritis reumatoide recibiendo upadacitinib: resultados de un estudio abierto de extensión de fase 2

RMD Open. 2022;8(1):e002110 doi: 10.1136/rmdopen-2021-002110

Winthrop K,

Vargas JI,

Drescher E,

Garcia C,

Friedman A,

Hendrickson B,

Li Y,

Klaff J,

Kivitz A

Vaccine sub-study of the BALANCE-EXTEND upadacitinib trial finds that approximately two-thirds of patients receiving upadacitinib 15 mg once-daily achieve a satisfactory humoral response to pneumococcal 13-valent conjugate (PCV-13) vaccine, despite receiving concomitant methotrexate (MTX).It is well known that a weakened immune response, comorbidities and immunosuppressant drug therapy all contribute to an increased susceptibility to infections in patients with RA. Likewise, the morbidity and mo...

Keywords:

• JAK,
• Updacitinib,
• Vaccination

Infecciones en los Ensayos Clínicos de Baricitinib en Pacientes con Artritis Reumatoide Activa

Annals of the Rheumatic Diseases, May 2020

Winthrop KL,

Harigai M,

Genovese MC,

Lindsey S,

Takeuchi T,

Fleischmann R,

Bradley JD,

Byers NL,

Hyslop DL,

Issa M,

Nishikawa A,

Rooney TP,

Witt S,

Dickson CL,

Smolen JS,

Dougados M

Baricitinib, an oral selective JAK1 and JAK2 inhibitor,8 demonstrated significant clinical efficacy in phase 3 RA trials. Pooled data from these trials, including a long-term extension (LTE), inform the safety profile for baricitinib, mainly to evaluate the incidence of infection in patients with active rheumatoid arthritis (RA), with a focus on serious infection, tuberculosis (TB), herpes zoster (HZ) and opportunistic infection (OI). The data collected were from eight double-blind randomised tr...

Keywords:

• JAK,
• Baricitinib,
• Safety,
• Infections

Efectividad a Largo Plazo de la Vacuna Viva Herpes Zoster en Pacientes con Artritis Reumatoide Tratados Posteriormente con Tofacitinib

Ann Rheum Dis. 2020 10.1136/annrheumdis-2019-216566

Winthrop KL,

Wouters A,

Choy EH,

Chen C,

Biswas P,

Wang L,

Soma K,

Needle E,

Valdez H,

Rigby WFC

The results of ORAL Sequel suggest that the live zoster vaccine (LZV) may not provide adequate long-term protection in patients with RA receiving TOF. This LTE study enrolled 100 patients with RA, 14 weeks post LZV vaccination. Patients received either TOF 5 mg BID, or TOF 10 mg BID in addition to any background csDMARDs. Incidence rates and 95% CIs for HZ post-vaccination were calculated based on time to first event. Short-term varicella zoster vaccine (VZV) specific immunity was evaluated at ...

Keywords:

• JAK,
• Tofacitinib,
• Vaccination

Eficacia Comparativa de Peficitinib 25, 50, 100 y 150mg en Pacientes con Artritis Reumatoide Activa: Un Metaanálisis Bayesiano en Red de Ensayos Controlados Aleatorizados

Clin Drug Investig .2020 Jan;40(1):65-72. doi: 10.1007/s40261-019-00863-9.

Lee YH,

Song GG

TOF significantly modulated the Th1 response to Varicella-zoster-virus (VZV). The poor VZV-specific cellular immune responses in patients with RA may be considered in recommendations regarding appropriate vaccination strategies for enhancing the VZV-specific Th1 response.Previous studies have shown that treatment with JAKinibs increases HZ incidence compared with conventional DMARDs. This cross-sectional in vitro study aimed to investigate the effect of TOF on the VZV-specific T cell immune resp...

Keywords:

• JAK,
• Peficitinib,
• Meta analysis

Eficacia Comparativa de Peficitinib 25, 50, 100 y 150mg en Pacientes con Artritis Reumatoide Activa: Un Metaanálisis Bayesiano en Red de Ensayos Controlados Aleatorizados

Rheumatology (Oxford) 2019;58(11):2051–60

Almanzar A,

Kienle F,

Schmalzing M,

Maas A,

Tony H-P,

Prelog M

TOF significantly modulated the Th1 response to Varicella-zoster-virus (VZV). The poor VZV-specific cellular immune responses in patients with RA may be considered in recommendations regarding appropriate vaccination strategies for enhancing the VZV-specific Th1 response.Previous studies have shown that treatment with JAKinibs increases HZ incidence compared with conventional DMARDs. This cross-sectional in vitro study aimed to investigate the effect of TOF on the VZV-specific T cell immune resp...

Keywords:

• JAK,
• Tofacitinib,
• MOA

Vacuna Viva Zoster en Pacientes con Artritis Reumatoide Tratados con Tofacitinib con o sin Metotrexato, o Adalimumab con Metotrexato

Arthritis Care and Research 2019 DOI: 10.1002/acr.24010

Calabrese LH,

Abud-Mendoza C,

Lindsey SM,

Lee SH,

Tatulych S,

Takiya L,

Iikuni N,

Soma K,

Luo Z,

Fleischmann R

Live zoster vaccine (LZV) was well tolerated, and herpes zoster (HZ) incidence rates were generally similar between treatment groups in vaccinated versus non-vaccinated patients in a subset of RA who received LZV before TOF ± MTX, or ADA + MTX, in ORAL Strategy. It is known that patient with RA are at increased risk of developing HZ though the mechanisms behind this are currently not well understood though therapies, such as TOF, are thought to increase the risk. ACR and EULAR recommend using LZ...

Keywords:

• JAK,
• Tofacitinib,
• Vaccination

Evaluación de las Respuestas Vacunales Neumocócica y Antitetánica en Pacientes con Artritis Reumatoide recibiendo Baricitinib: Resultados de un Subestudiode Extensión

Arthritis Res Ther. 2019 Apr 18;21(1):102

Winthrop KL,

Bingham CO III,

Komocsar WJ,

Bradley J,

Issa M,

Klar R,

Kartman CE

Approximately two thirds of long-term BARI treated patients achieved satisfactory humoral and functional responses to 13-serotype pneumococcal conjugate vaccine (PCV-13), whereas tetanus toxoid vaccine (TTV) responses were less robust. Both RA management guidelines and recommendations suggest vaccinating patients with RA against pneumococcal disease with PCV-13 and PPSV-23. The inhibition of the JAK mediated signal transduction pathways in RA treatment could diminish vaccine responses. Given the...

Keywords:

• JAK,
• Baricitinib,
• Vaccination

Herpes Zoster con Tofacitinib está aún más Aumentado con Glucocorticoides pero no con Metotrexate

Arthritis Care Res 2018 DOI 10.1002/acr.23769

Curtis JR,

Xie F,

Yang S,

Bernatsky S,

Chen L,

Yun H,

Winthrop K

The rate of Herpes Zoster (HZ) in tofacitinib (TOF) users with concomitant glucocorticoids (GC) was approximately double that of other TOF combination therapies.TOF is an effective treatment for RA. Increased HZ risk has been observed with the use of JAK inhibitors, whereas the HZ risk with biologics and targeted RA therapies are comparable. This study evaluated the HZ risk in TOF users according to concomitant GC, MTX, both, or neither. MarketScan and Medicare data were used to identify 8030 rh...

Keywords:

• JAK,
• Tofacitinib,
• Safety,
• Infections